Regeneron Pharmaceuticals, Inc. (REGN)
USD 564.26
(-1.6%)
USD 564.26
(-1.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.81 Billion USD | 25.8% |
| 2022 | 5.61 Billion USD | 19.86% |
| 2021 | 4.68 Billion USD | 23.33% |
| 2020 | 3.8 Billion USD | -21.98% |
| 2019 | 4.87 Billion USD | 30.17% |
| 2018 | 3.74 Billion USD | 10.21% |
| 2017 | 3.39 Billion USD | 5.13% |
| 2016 | 3.22 Billion USD | 31.35% |
| 2015 | 2.45 Billion USD | 38.45% |
| 2014 | 1.77 Billion USD | 49.33% |
| 2013 | 1.18 Billion USD | 42.22% |
| 2012 | 836.3 Million USD | 29.31% |
| 2011 | 646.76 Million USD | 16.65% |
| 2010 | 554.45 Million USD | 22.75% |
| 2009 | 451.68 Million USD | 37.98% |
| 2008 | 327.36 Million USD | 36.7% |
| 2007 | 239.47 Million USD | 46.96% |
| 2006 | 162.95 Million USD | 340.4% |
| 2005 | -67.78 Million USD | -144.26% |
| 2004 | 153.15 Million USD | 1.56% |
| 2003 | 150.8 Million USD | 9.71% |
| 2002 | 137.45 Million USD | 35.9% |
| 2001 | 101.14 Million USD | 46.62% |
| 2000 | 68.98 Million USD | 26.12% |
| 1999 | 54.7 Million USD | 19.43% |
| 1998 | 45.8 Million USD | 20.53% |
| 1997 | 38 Million USD | -5.71% |
| 1996 | 40.3 Million USD | 15.14% |
| 1995 | 35 Million USD | -33.21% |
| 1994 | 52.4 Million USD | 6.07% |
| 1993 | 49.4 Million USD | 65.77% |
| 1992 | 29.8 Million USD | 626.83% |
| 1991 | 4.1 Million USD | 105.0% |
| 1990 | 2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.98 Billion USD | 10.65% |
| 2024 Q1 | 1.83 Billion USD | -3.96% |
| 2024 Q2 | 1.85 Billion USD | 0.77% |
| 2023 Q3 | 1.71 Billion USD | -1.2% |
| 2023 Q4 | 1.91 Billion USD | 11.57% |
| 2023 FY | 7.06 Billion USD | 25.8% |
| 2023 Q1 | 1.7 Billion USD | 0.28% |
| 2023 Q2 | 1.73 Billion USD | 2.05% |
| 2022 Q2 | 1.25 Billion USD | -1.6% |
| 2022 Q4 | 1.69 Billion USD | 21.67% |
| 2022 FY | 5.61 Billion USD | 19.86% |
| 2022 Q1 | 1.27 Billion USD | -4.2% |
| 2022 Q3 | 1.39 Billion USD | 11.29% |
| 2021 FY | 4.68 Billion USD | 23.33% |
| 2021 Q2 | 1.09 Billion USD | -0.94% |
| 2021 Q1 | 1.1 Billion USD | 22.73% |
| 2021 Q4 | 1.32 Billion USD | 15.36% |
| 2021 Q3 | 1.15 Billion USD | 4.99% |
| 2020 FY | 3.8 Billion USD | -21.98% |
| 2020 Q4 | 902.8 Million USD | -6.63% |
| 2020 Q3 | 966.9 Million USD | -5.22% |
| 2020 Q2 | 1.02 Billion USD | 12.0% |
| 2020 Q1 | 910.8 Million USD | -28.28% |
| 2019 Q4 | 1.26 Billion USD | 17.23% |
| 2019 FY | 4.87 Billion USD | 30.17% |
| 2019 Q1 | 1.05 Billion USD | -3.65% |
| 2019 Q2 | 1.46 Billion USD | 39.24% |
| 2019 Q3 | 1.08 Billion USD | -26.08% |
| 2018 Q3 | 926.2 Million USD | 3.58% |
| 2018 Q2 | 894.17 Million USD | 7.82% |
| 2018 Q1 | 829.35 Million USD | -11.57% |
| 2018 FY | 3.74 Billion USD | 10.21% |
| 2018 Q4 | 1.09 Billion USD | 17.95% |
| 2017 Q3 | 836.51 Million USD | 2.4% |
| 2017 FY | 3.39 Billion USD | 5.13% |
| 2017 Q4 | 937.89 Million USD | 12.12% |
| 2017 Q1 | 804.28 Million USD | -0.11% |
| 2017 Q2 | 816.88 Million USD | 1.57% |
| 2016 Q2 | 851.96 Million USD | 12.13% |
| 2016 Q3 | 813.09 Million USD | -4.56% |
| 2016 FY | 3.22 Billion USD | 31.35% |
| 2016 Q1 | 759.78 Million USD | 0.48% |
| 2016 Q4 | 805.14 Million USD | -0.98% |
| 2015 Q3 | 635.91 Million USD | 12.57% |
| 2015 FY | 2.45 Billion USD | 38.45% |
| 2015 Q2 | 564.91 Million USD | 12.51% |
| 2015 Q4 | 756.16 Million USD | 18.91% |
| 2015 Q1 | 502.1 Million USD | 1.34% |
| 2014 FY | 1.77 Billion USD | 49.33% |
| 2014 Q3 | 487.47 Million USD | 22.82% |
| 2014 Q2 | 396.91 Million USD | 0.17% |
| 2014 Q1 | 396.22 Million USD | 13.14% |
| 2014 Q4 | 495.48 Million USD | 1.64% |
| 2013 Q2 | 259.92 Million USD | 0.92% |
| 2013 Q3 | 321.65 Million USD | 23.75% |
| 2013 FY | 1.18 Billion USD | 42.22% |
| 2013 Q4 | 350.22 Million USD | 8.88% |
| 2013 Q1 | 257.55 Million USD | 7.87% |
| 2012 FY | 836.3 Million USD | 29.31% |
| 2012 Q1 | 197.29 Million USD | 19.29% |
| 2012 Q2 | 195.07 Million USD | -1.12% |
| 2012 Q3 | 205.17 Million USD | 5.18% |
| 2012 Q4 | 238.76 Million USD | 16.37% |
| 2011 Q1 | 152.8 Million USD | 4.77% |
| 2011 FY | 646.76 Million USD | 16.65% |
| 2011 Q4 | 165.39 Million USD | 2.83% |
| 2011 Q3 | 160.84 Million USD | -4.11% |
| 2011 Q2 | 167.73 Million USD | 9.77% |
| 2010 Q3 | 137.7 Million USD | -1.08% |
| 2010 Q4 | 145.85 Million USD | 5.92% |
| 2010 FY | 554.45 Million USD | 22.75% |
| 2010 Q1 | 131.47 Million USD | -3.2% |
| 2010 Q2 | 139.2 Million USD | 5.88% |
| 2009 Q1 | 93.82 Million USD | 4.47% |
| 2009 Q2 | 105.86 Million USD | 12.84% |
| 2009 Q3 | 118.27 Million USD | 11.72% |
| 2009 Q4 | 135.82 Million USD | 14.84% |
| 2009 FY | 451.68 Million USD | 37.98% |
| 2008 Q3 | 85.22 Million USD | 6.47% |
| 2008 Q4 | 89.8 Million USD | 5.38% |
| 2008 FY | 327.36 Million USD | 36.7% |
| 2008 Q1 | 72.29 Million USD | -5.21% |
| 2008 Q2 | 80.04 Million USD | 10.72% |
| 2007 FY | 239.47 Million USD | 46.96% |
| 2007 Q4 | 76.26 Million USD | 25.07% |
| 2007 Q3 | 60.97 Million USD | 15.49% |
| 2007 Q2 | 52.79 Million USD | 6.8% |
| 2007 Q1 | 49.43 Million USD | 13.9% |
| 2006 Q3 | 40.82 Million USD | 0.32% |
| 2006 Q2 | 40.69 Million USD | 7.01% |
| 2006 Q1 | 38.03 Million USD | 118.64% |
| 2006 FY | 162.95 Million USD | 340.4% |
| 2006 Q4 | 43.4 Million USD | 6.31% |
| 2005 Q3 | 47.33 Million USD | 1.02% |
| 2005 Q1 | 42.05 Million USD | 6.09% |
| 2005 Q2 | 46.85 Million USD | 11.41% |
| 2005 FY | -67.78 Million USD | -144.26% |
| 2005 Q4 | -204.03 Million USD | -531.05% |
| 2004 Q3 | 37.01 Million USD | -8.68% |
| 2004 FY | 153.15 Million USD | 1.56% |
| 2004 Q1 | 35.97 Million USD | -4.09% |
| 2004 Q2 | 40.53 Million USD | 12.68% |
| 2004 Q4 | 39.64 Million USD | 7.11% |
| 2003 Q1 | 37.84 Million USD | 0.08% |
| 2003 FY | 150.8 Million USD | 9.71% |
| 2003 Q4 | 37.5 Million USD | -1.95% |
| 2003 Q3 | 38.25 Million USD | 2.81% |
| 2003 Q2 | 37.2 Million USD | -1.7% |
| 2002 Q1 | 28.87 Million USD | -12.05% |
| 2002 FY | 137.45 Million USD | 35.9% |
| 2002 Q2 | 33.65 Million USD | 16.56% |
| 2002 Q3 | 37.1 Million USD | 10.24% |
| 2002 Q4 | 37.82 Million USD | 1.93% |
| 2001 Q2 | 21.97 Million USD | 16.69% |
| 2001 FY | 101.14 Million USD | 46.62% |
| 2001 Q4 | 32.83 Million USD | 19.39% |
| 2001 Q3 | 27.5 Million USD | 25.12% |
| 2001 Q1 | 18.83 Million USD | -6.7% |
| 2000 FY | 68.98 Million USD | 26.12% |
| 2000 Q1 | 15.92 Million USD | 27.42% |
| 2000 Q2 | 17.16 Million USD | 7.78% |
| 2000 Q3 | 16.97 Million USD | -1.11% |
| 2000 Q4 | 20.18 Million USD | 18.92% |
| 1999 Q3 | 15.4 Million USD | 17.56% |
| 1999 Q4 | 12.5 Million USD | -18.83% |
| 1999 FY | 54.7 Million USD | 19.43% |
| 1999 Q1 | 13.5 Million USD | 12.5% |
| 1999 Q2 | 13.1 Million USD | -2.96% |
| 1998 Q3 | 11.9 Million USD | 2.59% |
| 1998 Q4 | 12 Million USD | 0.84% |
| 1998 FY | 45.8 Million USD | 20.53% |
| 1998 Q1 | 10.5 Million USD | 12.9% |
| 1998 Q2 | 11.6 Million USD | 10.48% |
| 1997 Q2 | 9.8 Million USD | 0.0% |
| 1997 FY | 38 Million USD | -5.71% |
| 1997 Q4 | 9.3 Million USD | 1.09% |
| 1997 Q3 | 9.2 Million USD | -6.12% |
| 1997 Q1 | 9.8 Million USD | -1.01% |
| 1996 FY | 40.3 Million USD | 15.14% |
| 1996 Q4 | 9.9 Million USD | -6.6% |
| 1996 Q3 | 10.6 Million USD | 7.07% |
| 1996 Q2 | 9.9 Million USD | 0.0% |
| 1996 Q1 | 9.9 Million USD | 16.47% |
| 1995 Q3 | 8.6 Million USD | -3.37% |
| 1995 Q4 | 8.5 Million USD | -1.16% |
| 1995 Q2 | 8.9 Million USD | -1.11% |
| 1995 Q1 | 9 Million USD | -29.69% |
| 1995 FY | 35 Million USD | -33.21% |
| 1994 Q4 | 12.8 Million USD | 1.59% |
| 1994 FY | 52.4 Million USD | 6.07% |
| 1994 Q1 | 13.4 Million USD | -68.54% |
| 1994 Q2 | 13.6 Million USD | 1.49% |
| 1994 Q3 | 12.6 Million USD | -7.35% |
| 1993 Q3 | 2.3 Million USD | -79.28% |
| 1993 Q2 | 11.1 Million USD | -1.77% |
| 1993 FY | 49.4 Million USD | 65.77% |
| 1993 Q1 | 11.3 Million USD | 34.52% |
| 1993 Q4 | 42.6 Million USD | 1752.17% |
| 1992 Q1 | 6.7 Million USD | 857.14% |
| 1992 Q2 | 6.7 Million USD | 0.0% |
| 1992 Q3 | 8 Million USD | 19.4% |
| 1992 Q4 | 8.4 Million USD | 5.0% |
| 1992 FY | 29.8 Million USD | 626.83% |
| 1991 FY | 4.1 Million USD | 105.0% |
| 1991 Q4 | 700 Thousand USD | -65.0% |
| 1991 Q1 | - USD | 100.0% |
| 1991 Q3 | 2 Million USD | 150.0% |
| 1991 Q2 | 800 Thousand USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q4 | -8.3 Million USD | 0.0% |
| 1990 FY | 2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -922.883% |
| Alkermes plc | 996.24 Million USD | -182.591% |
| Agenus Inc. | 78.18 Million USD | -3500.911% |
| Aptorum Group Limited | 10.56 Thousand USD | -26644798.732% |
| Ardelyx, Inc. | 169.93 Million USD | -1556.673% |
| Dyadic International, Inc. | 9.15 Million USD | -30659.243% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -12551.328% |
| Lantern Pharma Inc. | 17.87 Million USD | -15647.666% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -41720.015% |
| Novavax, Inc. | 779.12 Million USD | -261.341% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -3373.021% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -3325.106% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -14398.018% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -9409.221% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -5199.25% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -639.903% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -11482.447% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -7334.313% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -9049.199% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -3223.221% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -16027.055% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -1571.436% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -8505.533% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -1661.908% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -56.4% |
| AlloVir, Inc. | 180.93 Million USD | -1455.99% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -531.606% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -9384.873% |
| Bicycle Therapeutics plc | 216.92 Million USD | -1197.84% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -1537.735% |
| ChromaDex Corporation | 56.37 Million USD | -4893.526% |
| Chimerix, Inc. | 93.38 Million USD | -2914.595% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -20139.918% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -1770.184% |
| CRISPR Therapeutics AG | 463.49 Million USD | -507.408% |
| Precision BioSciences, Inc. | 92.46 Million USD | -2944.785% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -1008.194% |
| Fortress Biotech, Inc. | 200.19 Million USD | -1306.279% |
| Fortress Biotech, Inc. | 200.19 Million USD | -1306.279% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -8497.386% |
| ImmuCell Corporation | 9.61 Million USD | -29173.1% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -1683.936% |
| Immix Biopharma, Inc. | 16.14 Million USD | -17341.796% |
| Incyte Corporation | 1.19 Billion USD | -136.481% |
| Innoviva, Inc. | 132.15 Million USD | -2030.318% |
| IO Biotech, Inc. | 91.44 Million USD | -2978.749% |
| Jaguar Health, Inc. | 42.01 Million USD | -6600.702% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -1563.132% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -3238.709% |
| ContextLogic Inc. | 387 Million USD | -627.468% |
| MiMedx Group, Inc. | 229.72 Million USD | -1125.498% |
| MEI Pharma, Inc. | 34.78 Million USD | -7993.431% |
| NextCure, Inc. | 67.63 Million USD | -4062.367% |
| Onconetix, Inc. | 34.9 Million USD | -7965.045% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -21987.714% |
| Opthea Limited | 191.96 Million USD | -1366.551% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -102215.574% |
| Vaxcyte, Inc. | 468.04 Million USD | -501.507% |
| PDS Biotechnology Corporation | 43.04 Million USD | -6440.329% |
| Precigen, Inc. | 84.18 Million USD | -3244.341% |
| Pharming Group N.V. | 225.49 Million USD | -1148.52% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -1577.501% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -3779.641% |
| PureTech Health plc | 144.59 Million USD | -1846.998% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -2061.243% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -1048.361% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -11482.447% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -1131.109% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -9023.108% |
| Acelyrin, Inc. | 422.06 Million USD | -567.032% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -21834086.443% |
| Summit Therapeutics Inc. | 87.68 Million USD | -3110.661% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -7495.78% |
| Senti Biosciences, Inc. | 94.7 Million USD | -2872.705% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -2178.617% |
| Elevation Oncology, Inc. | 45.44 Million USD | -6094.961% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -9453.429% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -71317.192% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -2029.979% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -8159.645% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -33213.217% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -1452.832% |
| Seer, Inc. | 110.49 Million USD | -2448.013% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -3888.016% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -2911.725% |
| ESSA Pharma Inc. | 32.13 Million USD | -8661.097% |
| GlycoMimetics, Inc. | 39.28 Million USD | -7066.295% |
| GT Biopharma, Inc. | 13.57 Million USD | -20637.331% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -1180.671% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -1299.846% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -985.208% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -4860.094% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -5105.806% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -28229.65% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -597.611% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -14772.946% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -5453.627% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -984.23% |
| Aptose Biosciences Inc. | 52.35 Million USD | -5277.225% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -19436.62% |
| Soligenix, Inc. | 7.79 Million USD | -36015.579% |
| Century Therapeutics, Inc. | 56.07 Million USD | -4920.956% |
| Kura Oncology, Inc. | 165.8 Million USD | -1597.969% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -2358.627% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -33741.808% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -113345.187% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -2514.069% |
| Autolus Therapeutics plc | 196.72 Million USD | -1331.077% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -3225.537% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -2317.542% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -14424.583% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -774.974% |
| GRI Bio, Inc. | 11.33 Million USD | -24748.191% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -39801.067% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -2045.922% |
| IGM Biosciences, Inc. | 265.59 Million USD | -960.013% |
| INmune Bio, Inc. | 29.89 Million USD | -9316.979% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -1531.547% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -6883.376% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -17518.352% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -17784.512% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -4433.64% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -2518.348% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -921.172% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -833.916% |
| Verastem, Inc. | 92.08 Million USD | -2957.317% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -15593.739% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -1415.843% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -2218.894% |
| Histogen Inc. | 14.27 Million USD | -19626.037% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -17442.841% |
| Surrozen, Inc. | 18.55 Million USD | -15076.819% |
| Organovo Holdings, Inc. | 14.91 Million USD | -18775.629% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -55207.848% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -4617.867% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -10877.112% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -5889.235% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -36784.029% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -1480.422% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -5710.978% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -1049.083% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -18220.935% |
| Apollomics, Inc. | 54.14 Million USD | -5100.037% |
| Amarin Corporation plc | 272.35 Million USD | -933.68% |
| Mesoblast Limited | 5.9 Million USD | -47600.779% |
| Turnstone Biologics Corp. | 78.33 Million USD | -3493.786% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -1053.235% |
| Synaptogenix, Inc. | 8.31 Million USD | -33762.755% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -19201.385% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -1012.521% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -8346.725% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -31778.893% |
| Exelixis, Inc. | 1.58 Billion USD | -77.423% |
| Better Therapeutics, Inc. | 38.26 Million USD | -7257.953% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -1113.23% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -229.197% |
| NLS Pharmaceutics AG | 11.8 Million USD | -23744.202% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -34907.87% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -9286.524% |
| Gritstone bio, Inc. | 148.37 Million USD | -1797.435% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -3988.381% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -17108.206% |
| Avid Bioservices, Inc. | 25.99 Million USD | -10729.743% |
| Insmed Incorporated | 949.26 Million USD | -196.578% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -17843.518% |
| MediWound Ltd. | 18.86 Million USD | -14821.03% |
| OmniAb, Inc. | 83.89 Million USD | -3255.742% |
| Alector, Inc. | 248.8 Million USD | -1031.542% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -1101.538% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -5288.031% |
| Zai Lab Limited | 547.47 Million USD | -414.233% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -606.201% |
| Aura Biosciences, Inc. | 84.99 Million USD | -3212.468% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -1039.161% |
| Immunic, Inc. | 99.22 Million USD | -2737.346% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -1670.495% |
| Veracyte, Inc. | 357.93 Million USD | -686.544% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 68.774% |
| FibroGen, Inc. | 398.11 Million USD | -607.161% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -19712.104% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -40772.846% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -39408.923% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 13.525% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -10781.228% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -789.389% |
| TG Therapeutics, Inc. | 198.47 Million USD | -1318.466% |
| Galecto, Inc. | 35.62 Million USD | -7802.153% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -6819.069% |
| Fortrea Holdings Inc. | 457.3 Million USD | -515.635% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -5086.816% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -9648.944% |
| XBiotech Inc. | 37.51 Million USD | -7405.465% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -3988.381% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -13534.074% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -1881.754% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -2741.585% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -2442.812% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -193.797% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -9660.097% |
| Vaxxinity, Inc. | 56.05 Million USD | -4922.747% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -553.748% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -12519.959% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -2439.349% |
| NexImmune, Inc. | 28.16 Million USD | -9894.849% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -50800.858% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -15634.516% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -10958.172% |
| Scopus BioPharma Inc. | 11.71 Million USD | -23931.836% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -2115.69% |
| Ainos, Inc. | 12.95 Million USD | -21635.299% |
| Pluri Inc. | 22.48 Million USD | -12423.577% |
| Prothena Corporation plc | 282.4 Million USD | -896.898% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -1307.495% |
| Celularity Inc. | 215.05 Million USD | -1209.089% |
| Rallybio Corporation | 78.93 Million USD | -3466.741% |
| Cue Biopharma, Inc. | 19.54 Million USD | -14306.407% |
| MeiraGTx Holdings plc | 151.07 Million USD | -1763.474% |
| Omeros Corporation | 94.75 Million USD | -2871.262% |
| Humacyte, Inc. | 23.49 Million USD | -11881.53% |
| Immunocore Holdings plc | 308.04 Million USD | -813.94% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -82947.198% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -3141.006% |
| Blueprint Medicines Corporation | 722.86 Million USD | -289.466% |
| CalciMedica, Inc. | 21.81 Million USD | -12804.157% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -3670.828% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -1653.644% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -1543.539% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -854.533% |
| Pulmatrix, Inc. | 22.03 Million USD | -12674.753% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -8042.589% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -3068.028% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -410.419% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -3780.443% |
| Cytokinetics, Incorporated | 173.61 Million USD | -1521.604% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -8079.494% |
| Nutriband Inc. | 5.73 Million USD | -48998.095% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -6355.185% |
| Vor Biopharma Inc. | 126.03 Million USD | -2133.727% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -136.743% |
| Evogene Ltd. | 27.79 Million USD | -10030.623% |
| ProKidney Corp. | 151.52 Million USD | -1758.014% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -3695.484% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -36499.213% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -358.348% |
| CorMedix Inc. | 48.95 Million USD | -5650.464% |
| BioLineRx Ltd. | 50.8 Million USD | -5441.711% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -1768.149% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -7294.673% |
| Atai Life Sciences N.V. | 125.78 Million USD | -2138.184% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -3348.462% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -3358.217% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -1014.741% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -8498.962% |
| MediciNova, Inc. | 10.9 Million USD | -25727.812% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -2085.453% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -38680.78% |
| GeoVax Labs, Inc. | 6.02 Million USD | -46648.906% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -491.003% |
| Biomea Fusion, Inc. | 126.13 Million USD | -2131.974% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | -114.607% |
| Mereo BioPharma Group plc | 35.84 Million USD | -7754.751% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -1373.293% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -1124.288% |
| Absci Corporation | 73.66 Million USD | -3721.709% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -10107.019% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -2007.418% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -1062.569% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -974.345% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -1253.549% |
| Allakos Inc. | 196.05 Million USD | -1335.967% |
| Imunon, Inc. | 20.31 Million USD | -13761.354% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -2381.118% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -663.757% |
| BioAtla, Inc. | 129.68 Million USD | -2070.842% |
| NLS Pharmaceutics AG | 11.8 Million USD | -23744.202% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -17669.993% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -3215.316% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -6641.942% |
| XOMA Corporation | 46.46 Million USD | -5959.23% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -2432.405% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1876.162% |
| aTyr Pharma, Inc. | 12.97 Million USD | -21591.193% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -2616.003% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -1528.565% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -1005.062% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -7425.93% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -34129.345% |
| Akari Therapeutics, Plc | 16.8 Million USD | -16651.755% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -123705.503% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -840.572% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -41739.991% |
| UroGen Pharma Ltd. | 138.88 Million USD | -1927.029% |
| Sutro Biopharma, Inc. | 243 Million USD | -1058.517% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -38600.293% |
| Orgenesis Inc. | 45.75 Million USD | -6052.72% |
| Entera Bio Ltd. | 8.86 Million USD | -31675.395% |
| GH Research PLC | 41.22 Million USD | -6729.606% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -10851.066% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -3289.763% |
| Xencor, Inc. | 306.97 Million USD | -817.105% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -56963.738% |
| Replimune Group, Inc. | 234.77 Million USD | -1099.158% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -13639.948% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -1367.862% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -41739.991% |
| Portage Biotech Inc. | 18.19 Million USD | -15369.531% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -38680.78% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -2582.234% |
| OncoCyte Corporation | 25.63 Million USD | -10881.394% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -46085.72% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -24472.619% |
| Purple Biotech Ltd. | -22.46 Million USD | 12630.823% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -16983.131% |
| scPharmaceuticals Inc. | 65.17 Million USD | -4219.402% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -33206.376% |
| HilleVax, Inc. | 133.34 Million USD | -2011.29% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -27272.873% |
| Tharimmune, Inc. | 9.45 Million USD | -29675.087% |
| Genprex, Inc. | 31.06 Million USD | -8963.904% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -1401.285% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -8872.496% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -367913.072% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -51586.1% |
| OKYO Pharma Limited | 8243.57 USD | -34151365.93% |
| Savara Inc. | 15.74 Million USD | -17780.597% |
| Curis, Inc. | 58.35 Million USD | -4724.437% |
| Daré Bioscience, Inc. | 33.6 Million USD | -8276.525% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -55183.39% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -37633.548% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -10318.548% |
| BeiGene, Ltd. | 3.28 Billion USD | 14.34% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -14019.352% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -464.454% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -1732.257% |
| Erasca, Inc. | 141.52 Million USD | -1889.26% |
| bluebird bio, Inc. | 240.23 Million USD | -1071.909% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -62089.445% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -61.217% |
| DBV Technologies S.A. | 92.16 Million USD | -2954.796% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -62089.445% |
| Moderna, Inc. | 6.39 Billion USD | 55.97% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -6507.29% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -19496.965% |
| Molecular Templates, Inc. | 63.09 Million USD | -4362.285% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -4120.776% |
| Travere Therapeutics, Inc. | 472 Million USD | -496.459% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -1864.469% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -4434.809% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -6384.774% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -1252.664% |
| MacroGenics, Inc. | 217.21 Million USD | -1196.089% |
| RenovoRx, Inc. | 11.39 Million USD | -24604.282% |
| Adicet Bio, Inc. | 152.03 Million USD | -1751.708% |
| Prime Medicine, Inc. | 186.63 Million USD | -1408.42% |
| Aditxt, Inc. | 25.95 Million USD | -10748.62% |
| Adagene Inc. | 41.83 Million USD | -6630.119% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -38412.48% |
| Quantum-Si incorporated | 111.65 Million USD | -2421.337% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -1538.231% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -19212.284% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -7759.137% |
| SciSparc Ltd. | 9.01 Million USD | -31142.925% |
| Vericel Corporation | 142.04 Million USD | -1882.047% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -32421.766% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -12093.467% |
| Generation Bio Co. | 144.46 Million USD | -1848.75% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -3290.702% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -3156.188% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -852.015% |
| Invivyd, Inc. | 205.75 Million USD | -1268.278% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -3801.523% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -29918.647% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -3641.064% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -27267.551% |
| 2seventy bio, Inc. | 289.88 Million USD | -871.172% |
| ADMA Biologics, Inc. | 66.58 Million USD | -4128.066% |
| Clene Inc. | 41.07 Million USD | -6754.381% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -21880.989% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -5037.784% |
| GeoVax Labs, Inc. | 6.02 Million USD | -46648.906% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -699.692% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -7564.431% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -8247.071% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -2614.798% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -8538.805% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -1553.355% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -266.709% |
| Evaxion Biotech A/S | 22.27 Million USD | -12541.67% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -1977.038% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -1098.602% |
| Trevena, Inc. | 38.41 Million USD | -7229.029% |
| Surrozen, Inc. | 18.55 Million USD | -15076.819% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -3421.546% |
| Cingulate Inc. | 22.75 Million USD | -12269.949% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 37677.416% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -6202.863% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -34091.404% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -2645.081% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -273.34% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -4435.393% |
| Clearmind Medicine Inc. | 8.74 Million USD | -32106.696% |
| Kronos Bio, Inc. | 128.11 Million USD | -2097.427% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -3248.677% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -95887.535% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -2692.208% |
| Statera Biopharma, Inc. | 28.82 Million USD | -9665.342% |
| ImmunityBio, Inc. | 362.87 Million USD | -675.838% |
| Korro Bio, Inc. | 84.53 Million USD | -3230.376% |
| Kineta, Inc. | 21.15 Million USD | -13207.336% |
| BioVie Inc. | 31.95 Million USD | -8711.523% |
| Codexis, Inc. | 66.51 Million USD | -4132.388% |
| Celularity Inc. | 215.05 Million USD | -1209.089% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -1142.294% |
| Celcuity Inc. | 66.23 Million USD | -4150.771% |
| Virax Biolabs Group Limited | 6.54 Million USD | -42900.961% |
| Cibus, Inc. | 320.3 Million USD | -778.944% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -6447.209% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -8218.461% |
| IN8bio, Inc. | 30.33 Million USD | -9180.087% |
| Kodiak Sciences Inc. | 277.32 Million USD | -915.177% |
| Annexon, Inc. | 143.72 Million USD | -1858.837% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -2106.504% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -12189.057% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -439790.625% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -261.127% |
| Eyenovia, Inc. | 25.4 Million USD | -10981.046% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -1906.414% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -50516.685% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -3457.681% |
| Arcellx, Inc. | 200.19 Million USD | -1306.251% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -6033.551% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -1200.904% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -28174.581% |
| Moolec Science SA | 52.75 Million USD | -5237.0% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -4504.828% |
| Geron Corporation | 70.44 Million USD | -3896.678% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -5949.205% |
| Royalty Pharma plc | 862.4 Million USD | -226.448% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -2892.708% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -30081.609% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -12341.372% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -1254.734% |
| Humacyte, Inc. | 23.49 Million USD | -11881.53% |
| Structure Therapeutics Inc. | 102.77 Million USD | -2639.285% |
| 89bio, Inc. | 151.2 Million USD | -1761.922% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -3413.328% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -19262.448% |
| Genelux Corporation | 24.33 Million USD | -11468.934% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -8199.089% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -1528.574% |
| Notable Labs, Ltd. | 14.77 Million USD | -18960.934% |
| Liquidia Corporation | 87.98 Million USD | -3099.786% |
| Mustang Bio, Inc. | 48.5 Million USD | -5704.623% |
| Immunovant, Inc. | 282.7 Million USD | -895.83% |
| Quantum-Si incorporated | 111.65 Million USD | -2421.337% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -12388.023% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -13137.88% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -2659.773% |
| Acasti Pharma Inc. | 11.3 Million USD | -24811.955% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -12182.567% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -17518.352% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -5948.945% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -248035.874% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -17621.893% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -9555.657% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -6702.871% |
| PepGen Inc. | 84.76 Million USD | -3221.261% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -9401.198% |
| United Therapeutics Corporation | 885.1 Million USD | -218.077% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -12195.497% |
| Solid Biosciences Inc. | 104.31 Million USD | -2598.845% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -8502.763% |
| Immuneering Corporation | 58.41 Million USD | -4719.656% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -55207.848% |
| Silo Pharma, Inc. | 3.92 Million USD | -71684.89% |
| Belite Bio, Inc | 31.66 Million USD | -8790.047% |
| XOMA Corporation | 46.46 Million USD | -5959.23% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -4067.728% |
| Bionomics Limited | 17.89 Billion USD | 84.265% |
| Apogee Therapeutics, Inc. | 93 Million USD | -2927.107% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 7990.415% |
| uniQure N.V. | 285.08 Million USD | -887.527% |
| Cassava Sciences, Inc. | 105.95 Million USD | -2557.021% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -38412.48% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -1349.639% |
| Forte Biosciences, Inc. | 32.47 Million USD | -8568.597% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -33783.536% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -9477.479% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -50516.685% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -19712.104% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -31571.729% |
| Altimmune, Inc. | 30.55 Million USD | -9113.575% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -558.317% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 7990.415% |
| Compugen Ltd. | 43.97 Million USD | -6302.629% |
| Peak Bio, Inc. | 1249.13 USD | -225380765.082% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -3698.3% |
| Benitec Biopharma Inc. | 22.38 Million USD | -12478.411% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -1057.659% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -9763.364% |
| Zura Bio Limited | 62.63 Million USD | -4394.556% |
| PolyPid Ltd. | 21.04 Million USD | -13277.524% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -17197.247% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -9763.364% |
| Instil Bio, Inc. | 85.78 Million USD | -3181.809% |
| argenx SE | 1.53 Billion USD | -83.583% |
| Immunome, Inc. | 122.82 Million USD | -2192.216% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -5707.976% |
| Verona Pharma plc | 67.15 Million USD | -4092.474% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -10776.183% |
| Shattuck Labs, Inc. | 93.61 Million USD | -2907.349% |
| CervoMed Inc. | 14.95 Million USD | -18721.66% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -3881.868% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -32850.609% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -5420.196% |
| Moolec Science SA | 52.75 Million USD | -5237.0% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -17015.909% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -2023.871% |
| AnaptysBio, Inc. | 181.56 Million USD | -1450.549% |
| Design Therapeutics, Inc. | 78.19 Million USD | -3500.588% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -3134.453% |
| NeurAxis, Inc. | 8.82 Million USD | -31815.163% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -22270.282% |
| Lumos Pharma, Inc. | 38.66 Million USD | -7181.262% |
| Achilles Therapeutics plc | 75.25 Million USD | -3641.014% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -10776.183% |
| 180 Life Sciences Corp. | 13.47 Million USD | -20788.889% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -10522.795% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -95887.535% |
| Nutriband Inc. | 5.73 Million USD | -48998.095% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -2441.343% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -4958.667% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -5433.324% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -4159.217% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -5101.661% |
| Palisade Bio, Inc. | 13.32 Million USD | -21035.886% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -6099.872% |
| Beam Therapeutics Inc. | 554.19 Million USD | -407.999% |
| Neurogene Inc. | 55.58 Million USD | -4965.038% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -1032.968% |
| AEON Biopharma, Inc. | 48.42 Million USD | -5713.252% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -2811.074% |
| Sesen Bio, Inc. | 78.38 Million USD | -3491.814% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -3270.446% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -22266.912% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -524.245% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -3103.209% |
| Athira Pharma, Inc. | 125.46 Million USD | -2143.875% |
| Vaccinex, Inc. | 23.45 Million USD | -11902.984% |
| HCW Biologics Inc. | 21.02 Million USD | -13288.645% |
| XOMA Corporation | 46.46 Million USD | -5959.23% |
| Nektar Therapeutics | 190.9 Million USD | -1374.728% |
| Arvinas, Inc. | 480 Million USD | -486.521% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -123705.503% |
| Merus N.V. | 200.49 Million USD | -1304.182% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -2623.913% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -8032.005% |
| Rezolute, Inc. | 70.38 Million USD | -3899.744% |
| Clene Inc. | 41.07 Million USD | -6754.381% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -17089.025% |
| BeyondSpring Inc. | 24.86 Million USD | -11222.341% |
| Synlogic, Inc. | 58.53 Million USD | -4709.848% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -15634.965% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -62573.642% |
| Peak Bio, Inc. | 1249.13 USD | -225380765.082% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -4557.546% |
| Krystal Biotech, Inc. | 160.42 Million USD | -1654.89% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -940.273% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -708.906% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -130435.337% |
| MannKind Corporation | 125.59 Million USD | -2141.534% |
| Ikena Oncology, Inc. | 84.57 Million USD | -3228.683% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -29083.166% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -3042.041% |
| Gossamer Bio, Inc. | 183.75 Million USD | -1432.061% |
| CohBar, Inc. | 12.38 Million USD | -22625.48% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -5450.233% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -10107.019% |
| Legend Biotech Corporation | 583.14 Million USD | -382.779% |
| Mural Oncology plc | 192.07 Million USD | -1365.76% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -4092.741% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -17337.304% |
| Disc Medicine, Inc. | 91.12 Million USD | -2989.492% |
| Champions Oncology, Inc. | 28.11 Million USD | -9915.297% |
| REGENXBIO Inc. | 321.15 Million USD | -776.612% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -52412.164% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -4949.322% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -7126.01% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -2361.852% |
| Vaxart, Inc. | 90.72 Million USD | -3003.08% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -32943.396% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -6478.713% |
| Cellectis S.A. | 97.32 Million USD | -2792.828% |
| Longeveron Inc. | 21.25 Million USD | -13148.471% |
| Repare Therapeutics Inc. | 167.35 Million USD | -1582.212% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -106.883% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -3621.726% |
| Revolution Medicines, Inc. | 498.76 Million USD | -464.454% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -42222.61% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -6305.105% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -3674.367% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -3942.938% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -25354.792% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 41.041% |
| Denali Therapeutics Inc. | 527.23 Million USD | -433.979% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -32421.766% |
| Veru Inc. | 101.34 Million USD | -2677.851% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -11927.599% |
| Cingulate Inc. | 22.75 Million USD | -12269.949% |
| Passage Bio, Inc. | 108.38 Million USD | -2497.404% |
| Context Therapeutics Inc. | 25.07 Million USD | -11128.585% |
| Exicure, Inc. | 14.07 Million USD | -19900.71% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -1266.226% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -6401.697% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -30576.812% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -1015.045% |
| Nuvalent, Inc. | 149.49 Million USD | -1783.245% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -34799.395% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -2616.16% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -13025.554% |
| OmniAb, Inc. | 83.89 Million USD | -3255.742% |
| Anew Medical, Inc. | 1.3 Million USD | -216321.53% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -8492.663% |
| Lipocine Inc. | 15.08 Million USD | -18568.926% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -4009.147% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -3596.948% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -6883.376% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -2351.434% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -12477.287% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -323.898% |
| Ocugen, Inc. | 71.56 Million USD | -3833.796% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -2899.276% |
| Q32 Bio Inc. | 92.68 Million USD | -2937.656% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -13196.023% |
| Alumis Inc. Common Stock | 158.17 Million USD | -1679.875% |
| Equillium, Inc. | 50.6 Million USD | -5463.174% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -4411.265% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -20145.866% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -14823.318% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -5896.251% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -2495.56% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -22617.357% |
| Dominari Holdings Inc. | 23.83 Million USD | -11711.622% |
| Edesa Biotech, Inc. | 9.22 Million USD | -30425.576% |
| vTv Therapeutics Inc. | 11.9 Million USD | -23544.075% |
| Bio-Techne Corporation | 563.03 Million USD | -400.019% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -588.664% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -947.53% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -2028.337% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -19435.771% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -1619.834% |
| Nkarta, Inc. | 131.65 Million USD | -2038.473% |
| BioCardia, Inc. | 12.12 Million USD | -23126.631% |
| Iterum Therapeutics plc | 47.46 Million USD | -5830.943% |